Discussion
GV300, an experimental treatment being developed by Graviton Bioscience for progressive forms of multiple sclerosis (MS), reduced inflammation and myelin damage and promoted myelin repair in mouse models of the disease. The findings, presented at the Neuroscience 2026 conference, suggest that targeting a protein called…